Page last updated: 2024-09-03

omega-n-methylarginine and Neurally Mediated Faint

omega-n-methylarginine has been researched along with Neurally Mediated Faint in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Goetz, AM; Kothari, ML; Medow, MS; Stewart, JM; Sutton, R; Visintainer, P1
Medow, MS; Merchant, S; Stewart, JM; Suggs, M; Sutton, R; Terilli, C; Visintainer, P1

Other Studies

2 other study(ies) available for omega-n-methylarginine and Neurally Mediated Faint

ArticleYear
Nitric oxide synthase inhibition restores orthostatic tolerance in young vasovagal syncope patients.
    Heart (British Cardiac Society), 2017, Volume: 103, Issue:21

    Topics: Administration, Intravenous; Adolescent; Adult; Age Factors; Arterial Pressure; Arteries; Cardiac Output; Enzyme Inhibitors; Female; Hemodynamics; Humans; Lower Body Negative Pressure; Male; Nitric Oxide Synthase; omega-N-Methylarginine; Syncope, Vasovagal; Time Factors; Treatment Outcome; Vascular Resistance; Vasoconstriction; Young Adult

2017
Postsynaptic α1-Adrenergic Vasoconstriction Is Impaired in Young Patients With Vasovagal Syncope and Is Corrected by Nitric Oxide Synthase Inhibition.
    Circulation. Arrhythmia and electrophysiology, 2016, Volume: 9, Issue:8

    Topics: Adolescent; Adult; Cardiac Output; Enzyme Inhibitors; Female; Heart Rate; Humans; Male; Nitric Oxide Synthase; omega-N-Methylarginine; Phenylephrine; Splanchnic Circulation; Syncope, Vasovagal; Treatment Outcome; Vascular Resistance; Vasoconstriction

2016